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ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine is Kava (piper
methysticum) safe and effective for reducing anxiety in adult patients 18-65?
STUDY DESIGN: Review of three English language primary randomized controlled studies
published from 2005-2009.
DATA SOURCES: Randomized, double blind, placebo-controlled trials comparing Kava and
placebo were found using OVID, PubMed, and CINAHL and COCHRANE databases.
OUTCOMES MEASURED: Each of the three trials assessed the adverse event of hepatotoxicity
and clinical improvement in anxiety symptoms. Studies utilized to measure change in anxiety
symptoms included State Trait Anxiety Inventory (STAI-state), Hamilton Anxiety Scale
(HAMA), the Hospital Anxiety and Depression Scale (HADS), Sheehan Disability Inventory
(SDI), and Beck Depression Inventory-II (BDI-II).
RESULTS: Three double-blind randomized controlled trials were included in this review.
Results from the Conner et al study indicate that Kava use is effective in reducing anxiety in
individuals with low baseline anxiety, but there were no differences between Kava and placebo
when HAMA scores were > 16 or > 18. The second study by Sarris et al concluded that the
response rate after treatment with Kava was 62% with a remission rate of 35%. The third study
by Jacobs et al showed a reduction in anxiety symtpoms, but not greater than that of placebo;
however, the data was not statistically significant. All three trials demonstrated that kava use
does not contribute to hepatotoxicity.
CONCLUSIONS: All of the RCTs demonstrate that Kava use is safe and effective at reducing
anxiety. However, it seems to be a less efficient option in the overall anxiety score reduction
when compared to the current available treatment. In addition, the studies failed to demonstrate
that Kava has an effect on hepatotoxicity.
KEY WORDS: Kava (piper methysticum), anxiety

INTRODUCTION
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Anxiety is becoming an increasing health concern among the general population. It
encompasses an extensive range of conditions including: post-traumatic stress disorder,
obsessive compulsive disorder, panic disorder, phobias, and generalized anxiety disorder (GAD).
It is the most common mental disorder that affects more than 18% of the U.S. population 18
years and older (40 million); GAD accounts for 6.8 million, or 3.1%.1 By disrupting the central
nervous system, specifically sympathetic response, anxiety leads to both psychological and
physiological manifestations.2 This paper evaluates three double blind, placebo-controlled,
randomized controlled trials (RCTs), comparing the safety and efficacy of Kava for reducing
generalized anxiety in adults.
Anxiety is relevant to the Physician Assistant profession due to its high rates of
prevalence today. Half of all PAs work in a primary care setting, where GAD is very common,
accounting for 3-8% of yearly office visits, (>6.8 million).3,4 It accounts for almost one third of
the total health expenses for mental illness, with an estimated $42 billion spent yearly.
Additionally, anxiety sufferers are three to five times more likely to seek medical care and six
times more likely to be hospitalized than those without anxiety.1 Recent data shows that a
quarter of the population will at some point experience anxiety that severely impacts their daily
activities, including sleep, appetite, and thinking and are in need of prompt health professional
advice.5
Although the exact cause of GAD is unknown, it is believed to be as a result of underactivation of serotoninergic and over-stimulation of noradrenergic neurotransmitters, as well as
disturbance of the gamma-aminobutyric acid (GABA) system.2 It is characterized by frequent,
relentless worry and anxiety that is out of proportion to the situation for at least six months. 2,3
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Patients also often experience restlessness, fatigue, difficulty concentrating, irritability and

muscle disturbances. The diagnosis of GAD is made based on history and DSM IV criteria. It
can be rated by the Hamilton Anxiety Scale (HAMA) based on symptom severity, such as:
behavior, anxious/depressed mood, fears, intellectual impairment, tension, insomnia
cardiovascular, respiratory, GI, GU, autonomic, or somatic symptoms.6
Usual methods used to treat anxiety disorder include a combination of psychotherapy and
pharmacotherapy. Cognitive Behavioral Therapy (CBT) has been proven to be most effective of
the psychotherapies available, and when used in conjunction with medicine demonstrates to be
twice as effective in establishing remission. Among the pharmacotherapy options,
benzodiazepines are best in management of short-term symptoms and for those with severe
impairment of function, in need of a quick-acting anxiolytic. However, due to their addiction
and withdrawal potential, selective serotonin reuptake inhibitors (SSRIs) are the best-tolerated
medications for long-term use. Given that SSRIs take 4-6 weeks to show symptom
improvement, currently, the initial best treatment option includes a combination of
benzodiazepines and SSRIs. 2
The above regimens are effective treatment options for patients with anxiety, although
most target multiple conditions and favorable effects and adverse reaction vary among each
patient. Additionally, they may need to be used long-term in order to prevent relapse, which
occurs in 25% of all patients within the first month of discontinuation, and in 60-80% over a
year. Kava may be a natural anxiolytic alternative to these regimens in the reduction of anxiety
and will be discussed further in this review.2

OBJECTIVE
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The objective of this selective EBM review is to determine, “Is Kava (piper methysticum)
safe and effective for reducing anxiety in adult patients 18-65?”
METHODS
The three studies utilized in this review were randomized controlled clinical trials and
met the following criteria: The population consisted of adults ages 18-65 who met DSM-IV
anxiety criteria. The intervention used was Kava 300mg, 280mg and 1,250mg. The treatment
group receiving Kava was compared to the group receiving a virtually matched placebo.
Outcomes measured included safety of Kava concerning drowsiness and hepatotoxicity and its’
efficacy regarding anxiety.
Key words used to locate the literature consisted of Kava (piper methysticum) and
anxiety. All articles were published in English and published in peer-reviewed journals. The
articles were researched by the author and obtained via OVID, PubMed, CINAHL, and
COCHRANE databases. Articles were selected based on relevance and significance of outcomes
to the patients (POEMS). Inclusion criteria consisted of double blind, RCT studies, included
patient oriented outcomes, and were published after 1996. Exclusion criteria included: patients
under 18 years old, recent anxiety/depression treatment or disorder, substance abuse,
breastfeeding, pregnancy, history of liver disease, lifetime history of bipolar disorder, psychiatric
disorder, organic brain syndrome, or mental retardation. Statistics that were reported and utilized
are relative risk (RR), relative risk reduction (RRR), absolute risk increase (ARI), absolute risk
reduction (ARR), number needed to harm (NNH), number needed to treat (NNT), p-value, and
χ²-distribution.7,8,9
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Demographics and characteristics of the studies utilized for this review are displayed in Table 1.
Table 1. Demographics and characteristics of included studies
Study
Type
#
Age
Inclusion
Exclusion
Pts
(yrs)
Criteria
Criteria
4
Jacobs , RCT 391 >21
Adults who
Pts who use
2005
(mean: scored > 40
sedative41.4)
points on STAI; hypnotic or
> 21 who reside benzos; drink >2
in US and have alcoholic drinks
access to email daily; hx of liver
and WWW with ds; pregnancy;
anxiety
breastfeeding
documented by
STAI 2 separate
times

Connor5,
2006

RCT

64

> 18
(mean:
52.5;
49.9;
43.6)

Adults with
DSM-IV GAD
– HAMA score
of 16, 12-20, or
18 with
symptoms for 6
mos

Sarris6,
2009

RCT

60

18-65
(mean:
44.4,
43.1)

Adults with at
least 1 mo of
persistent
worry/anxiety
scoring > 10 on
BAI

Hx of
anxiety/mental
ds; substance
abuse; abnl
lab/EKG;
psychotropic tx,
pregnancy;
breastfeeding
Hx of bipolar
psychosis;
suicide ideation;
substance abuse
within 6 mo; use
of
antidepressant,
benzos, or
opiates in past 1
mo; concurrent
psychological tx

W/D

Interventions

72

1) 1 100 mg
Kava softgel
capsule TID +
2 placebo
valerian softgel
capsules 1 hr
before bed
2) 2 3.2 mg
valerian softgel
capsule 1 hour
before bed + 1
placebo-Kava
softgel capsule
TID
3) PlaceboKava +
placebovalerian softgel
capsules
1 70 mg Kava
capsule BID x
1 week; then 1
140 mg Kava
BID

N/A

19

5 250 mg Kava
tabs QD x 3
weeks

OUTCOMES MEASURED
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All outcomes measured in the trials were based on patient oriented evidence that mattered
to the patients and assessed the adverse event of hepatotoxicity and clinical improvement in
anxiety symptoms. Jacobs et al measured the change in anxiety symptoms based on the State
subtest of the State Trait Anxiety Inventory (STAI-State) and reported adverse events throughout
the study, including hospitalizations, ER visits, or any new symptoms or illnesses by contacting
the on-call physician by e-mail or telephone.7 The Conner et al study made assessments via the
Hamilton Anxiety Scale (HAMA): scored 0 to 4, the Hospital Anxiety and Depression Scale
(HADS), and the Sheehan Disability Inventory (SDI).8 The Sarris et al study participants were
assessed on the HAMA Scale, Beck Depression Inventory-II (BDI-II): 21 questions scored 0 to
3, and were asked to obtain liver function tests within 3 days.9

RESULTS
The results of two of the three trials, Jacobs et al and Connor et al, converted continuous
data into dichotomous in order to assess the symptomatic improvement in anxiety and the safety
of Kava use. The Sarris et al study used continuous data that could not be converted to
dichotomous.
Connor et al study stratified participants based on the baseline entry criterion scores; it
demonstrated that daily use of 280 mg Kavalactones titrated for a total of four week duration was
effective in reducing generalized anxiety in individuals with low baseline anxiety (HAMA entry
scores 12-20), yet no differences between Kava and placebo were found when HAMA scores
were > 16 or > 18 with four and eight weeks of treatment, respectively (Table 2). Furthermore,
the RRR was calculated to be 25% and the ARR was 5%. NNT was 20 patients and the p-value
was determined to be statistically significant at p<0.04 and p<0.05 on the HAMA and HADS
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assessments (Table 3). The NNT value indicates that for every 20 patients treated with 280 mg
of Kava daily, one more patient would have complete remission of anxiety than if treated with
placebo. In addition, in this limited sample, Kava use appeared safe with respect to liver
function, with all values remaining well below the normal reference range (Table 4).

Table 2. Baseline entry criteria and symptom severity before and after treatment
Study
Treatment Patients
Entry Criteria
Before
After
Anxiety
Duration
(n)
Reduction *
HAMA
4 weeks
35
Baseline HAMA > Kava: 21
Kava: 13
Kava: 8
Trial 1
16
Placebo: 18 Placebo: 10 Placebo: 8
HAMA
4 weeks
13
Baseline HAMA
Kava: 17
Kava: 7.5
Kava: 9.5
Trial 2
12-20
Placebo: 14 Placebo: 10 Placebo: 4
HAMA
8 weeks
16
Baseline HAMA > Kava: 32
Kava: 20
Kava: 12
Trial 3
18
Placebo: 24 Placebo: 12 Placebo: 12
HAMA: Hamilton Anxiety Scale
* Points reduction in HAMA score before and after treatment with Kava and placebo
Table 3. Analysis of efficacy of Kava use for remission of generalized anxiety.
Study
Relative risk
Absolute risk
Number needed to
p-value
reduction (RRR)
reduction (ARR)
treat (NNT)
Connor5, 2006
25%
5%
20 patients
HAMA: p<0.04
HADS: p<0.05
Table 4. 8
Comparison of liver enzyme scores after treatment with Kava and placebo (mean SD)
_______________Treatment__________________
Before
After
P
SGOT
Kava
25.9 (6.8)
30.0 (14.5)
NS
Placebo
26. 8 (9.5)
24.6 (5.0)
SGPT
Kava
27.9 (13.8)
34.3 (24.7)
NS
Placebo
28.0 (12.6)
26.7 (9.1)
Alkaline Phosphatase
Kava
67.9 (16.9)
69.6 (14.4)
NS
Placebo
67.6 (12.0)
63.2 (19.8)
Total bilirubin
Kava
0.55 (0.23)
0.50 (0.24)
NS
Placebo
0.49 (0.20)
0.48 (0.18)
Reference ranges: serum glutamate-oxaloacetate transaminase (SGOT): 10-60 U/l; serum
glutamate-pyruvate transaminase (SGPT): 10-60 U/l; alkaline phosphatase: 30-135 U/l; total
bilirubin: 0.2-1.2 mg/dl
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Sarris et al study started with 182 volunteers, 141 of who were excluded due to no stable
anxiety symptoms, use of antidepressants or anti-anxiety medication, bipolar depression, liver
dysfunction, high alcohol or drug use, and positive placebo response. The primary result
outcomes were measured via HAMA with secondary outcomes measured by the BAI scale after
administration of 250 mg of Kava daily for a total of three weeks. The HAMA scale showed

statistically significant (p<0.0001) results where anxiety was reduced by -9.9 points (CI = -12.7,
-7.1) below pretreatment levels during the first controlled trial and by -10.3 (CI = -14.7, -5.8)
points during the second trial, compared with a -0.8 (CI = -4.3, +2.7) decrease with placebo use
during trial one, and an increase of +3.3 (CI = -0.2, +6.8) points in trial two. The BAI scale also
revealed statistically significant data (p=0.001) in support of Kava, with reduction by -7.2 (CI =
-10.8, -3.5) points and -8.1 (CI = -12.5, -3.6) for trial one and two, respectively. Placebo use in
trial one showed a -1.6 (CI = -5.6, +2.5) point reduction, and an increase of +1.4 (CI = -2.0,
+4.9) points in trial two (Table 5). In addition, serious adverse effects, including hepatotoxicity
were not evident in either trial based on participant reporting. Furthermore, the study concluded
that the response (> 50% reduction below baseline on HAMA) rate after treatment with Kava
was 62% with a remission rate of 35%. 9
Table 5. Symptom severity before and after treatment with Kava and placebo.9
Mean (SD)
Outcome
measure
HAMA

Pretreatment score (SD)

Trial 1

Trial 2

KP 21.16 (3.52)
KP 11.26 (4.47)
KP
PK 20.28 (4.78)
PK 19.50 (7.26)
PK
BAI
KP 16.47 (4.90)
KP 9.32 (6.49)
KP
PK 17.94 (5.98)
PK 16.39 (10.16)
PK
KP: Kava week 1, Placebo week 2; PK: Placebo week 1, Kava week 2

14.58 (5.86)
9.22 (5.96)
10.74 (6.04)
8.33 (7.39)

p
<0.0001
0.001

Jacobs et al converted continuous data into dichotomous for NNH, but no dichotomous
data was provided for NNT. To determine effectiveness in anxiety reduction, symptom severity
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was assessed using the STAI scale. Participants who received four weeks of Kava therapy had a
total reduction in anxiety of -11.8, whereas those on placebo had a reduction of -14.4 (Table 6).
However, this difference between groups is +2.7 with a 95% CI (-0.8, +6.2) and is not
statistically significant. All participants were contacted either by e-mail or postal mail
concerning hepatotoxicity, since this study was conducted before safety warnings were issued;
none of the participants reported any adverse events. Additionally, side effects of similar
frequency occurred between Kava and placebo groups.7 In regards to headache and drowsiness,
the RRI was calculated to be 21% and ARI -5%. NNH was -20 patients at a confidence interval
of 95%. The negative value of NNH shows that for every 20 patients treated with Kava, one
fewer patient would experience headache or drowsiness when compared to placebo.
Table 6. Symptom severity before and after treatment with Kava and placebo.
Mean (SD)
Outcome measure: Kava
STAI
(n=121)
Baseline
56.8 (9.6)
Week 2 – change
-9.2 (9.9)
from baseline
Week 4 – change
-11.8 (12.3)
from baseline
STAI: State-Trait Anxiety Inventory

Placebo
(n=135)
56.6 (9.3)
-11.1 (11.4)

Kava – Placebo
(95% CI)

-14.4 (12.9)

+2.7 (-0.8 to +6.2)

Table 7.
Analysis of safety of Kava use regarding headache and drowsiness for generalized anxiety.
Study
Relative risk
Absolute risk
Number needed
CI
increase (RRI)
increase (ARI)
to harm (NNH)
Jacobs4, 2005
- 21%
- 5%
-20 patients
95%
DISCUSSION
Kava is a native plant found in the South Pacific and has many reported uses, including
those for anxiety, insomnia, skeletal muscle relaxation, and ADD/ADHD in children. Its use as
an anxiolytic is becoming more popular, especially in Western Europe for the treatment of
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anxiety and nervous tension. It works by exerting its effects on the amygdala in the limbic

system, which is responsible for generation of emotion.8,10 Currently, the FDA is trying to
ascertain Kava’s effects on hepatotoxicity and the safety of its use. Presently, it is
contraindicated in pregnancy and lactation, as well as Parkinson’s disease due to it’s potential
dopamine antagonistic effects.10
As a result of hepatotoxicity, Kava use has been banned in the United States. However,
Kava use in regards to hepatotoxicity has been proven safe; the toxicity patterns that had seemed
to emerge may be as a result of difference in genetics and human metabolism. In addition, the
preparations used to make kava tablets, such as ethanol and the use of kava stems and leaves as
opposed to only the root extract is what had lead to hapatotoxicity and the current ban.
Moreover, studies have shown that Kava inhibits cytochrome isoenzymes 1A2, C29, 2C19, 2D6,
and 3A4 and concomitant use with other medications could lead to hepatotoxicity. Newer
formulations of Kava, which exclude methysticin and dihydromethysticin may lead to
developments of a safer form of Kava.8 Additionally, Kava side effects were comparable to and
possibly even superior to most benzodiazepine trials and did not demonstrate any withdrawal
effects upon discontinuation, as can be seen with benzodiazepines and SSRIs.8,9
Connor and Sarris et al studies showed a decrease in anxiety scores when compared to
placebo, while the Jacobs et al study shows Kava reduces symptoms of anxiety but not greater
than that of placebo. Although data in this review supports the use of Kava in reduction of
anxiety, not all of the data presented is clinically significant. Even though the three studies
provide adequate data, the small sample size may not be adequately large enough to show a
difference in treatment such as that of the Conner et al study that only shows effectiveness
among 13 participants with low base-line anxiety (HAMA score 12-20). In addition, this
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reduction may not be clinically significant enough to therapeutically be beneficial to patients
with generalized anxiety.

Certain limitations to the studies exist and many factors may have affected the outcome.
One of the factors is that participants have strong beliefs in the efficacy of natural alternatives,
which may have influenced response to treatment, thereby not showing a difference in Kava use
versus placebo. Limitations of the studies include: less consistent responses from patients that
used the internet for responses, resulting in misleading information; small sample sizes;
differences regarding duration of GAD prior to study entry and duration of treatment; and the
average patient population (50 years) is higher than the average age of participants with
GAD.7,8,9
CONCULSION:
Kava has been proven to be safe and effective at reducing anxiety in adults 18-65.
However, considering the inconsistencies and inconclusiveness of the data, other therapies may
be more beneficial at this time with pending FDA studies, which are thereby limiting further
research in the US currently. Therefore, it can be concluded that Kava therapy alone is a less
efficient treatment option, but is still successful in reducing anxiety with comparable side effects
to other available options. Further studies can refine the population of interest by setting a more
narrow age-requirement range; for example: 18-25; 26-33; 34-41; 42-50; 51-60. By targeting a
smaller population in similar age groups, the population better relates to one another and anxiety
and stress response at study initiation will not be as varied. Future studies can also do a pre and
post liver enzyme study among all participants to get a better understanding of hepatotoxicity.
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